Breakthrough in targeted therapy for non-small cell lung cancer - 19/12/20

Doi : 10.1016/j.biopha.2020.111079

Zhencong Ye ^a,^b,^{^{1
These authors contributed equally to this work.}}, Yongmei Huang ^a,^b,^c,^d,^{^{1
These authors contributed equally to this work.}}, Jianhao Ke ^e,^{^{1
These authors contributed equally to this work.}}, Xiao Zhu ^a,^b,^c,^d,⁎ , Shuilong Leng ^f,⁎ , Hui Luo ^a,^b,^c,^d,⁎
^a Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China
^b Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China
^c The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China
^d The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China
^e College of Agriculture, South China Agricultural University, Guangzhou, China
^f Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China

^⁎Corresponding authors at: Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.Guangdong Key Laboratory for Research and Development of Natural DrugsThe Marine Biomedical Research InstituteGuangdong Medical UniversityZhanjiangChina^⁎⁎Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas	10
Iconografías	1
Vídeos	0
Otros	0

Highlights

•	Targeted therapy has improved the survival rate and extended the survival time of patients.
•	Targeted therapy has greater advantages than chemotherapy with low side effects.
•	Discussing and comparing the advantages and disadvantages of multiple targeted inhibitors.

El texto completo de este artículo está disponible en PDF.

Abstract

Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.

El texto completo de este artículo está disponible en PDF.

Abbreviations : ALK, BBB, BIRC, DCR, EGFR, FISH, HR, mPFS, NSCLC, NCCN, ORR, OS, PFS, TKI

Keywords : Non-small cell lung cancer, Targeted therapy, Chemotherapy, EGFR, ALK

Esquema

Introduction

EGFR

The first-generation of EGFR-TKI

The second-generation of EGFR-TKI

The third-generation of EGFR-TKI

ALK

The first-generation of ALK inhibitor

The second-generation of ALK inhibitor

The third-generation of ALK inhibitor

Authors’ contributions

Exportación

Vol 133

Artículo 111079- janvier 2021 Regresar al número

Artículo precedente

Research progress on the role of gal-3 in cardio/cerebrovascular diseases
Zhan-Qi Cao, Xin Yu, Ping Leng

| Artículo siguiente

Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver
Han-Yu Lei, Ying-He Ding, Kai Nie, Yin-Miao Dong, Jia-Hao Xu, Meng-Ling Yang, Meng-Qi Liu, Le Wei, MI Nasser, Lin-Yong Xu, Ping Zhu, Ming-Yi Zhao

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

conectar o crear una cuenta

Breakthrough in targeted therapy for non-small cell lung cancer - 19/12/20

Highlights

Abstract

Esquema

Exportación citas

Fichero

Contenido

Mi cuenta

Aide & support

Declaración CNIL